These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15134183)

  • 21. Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.
    Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Intervirology; 2010; 53(3):176-82. PubMed ID: 20197684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
    Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
    AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE; Grintjes KJ; Telgt DS; Stek M; Hugen PW; Reiss P; Koopmans PP; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2002 Jan; 71(1):57-67. PubMed ID: 11823758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].
    Bani-Sadr F; Perré P; Peytavin G; Bernard L; Melchior JC; Perronne C; de Truchis P
    Presse Med; 2001 Apr; 30(15):731-5. PubMed ID: 11360738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
    Acosta EP; Wu H; Hammer SM; Yu S; Kuritzkes DR; Walawander A; Eron JJ; Fichtenbaum CJ; Pettinelli C; Neath D; Ferguson E; Saah AJ; Gerber JG;
    J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1358-66. PubMed ID: 15483465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.
    Solas C; Petit N; Orticoni M; Durand A; Gastaut JA; Lacarelle B
    Pathol Biol (Paris); 2002 Nov; 50(9):565-7. PubMed ID: 12490421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
    Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
    Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children.
    Plipat N; Cressey TR; Vanprapar N; Chokephaibulkit K
    Pediatr Infect Dis J; 2007 Jan; 26(1):86-8. PubMed ID: 17195716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
    Cressey TR; Urien S; Hirt D; Halue G; Techapornroong M; Bowonwatanuwong C; Leenasirimakul P; Treluyer JM; Jourdain G; Lallemant M;
    Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
    Pelton SI; Stanley K; Yogev R; Fletcher CV; McIntosh K; Wiznia A; Nachman S;
    Clin Infect Dis; 2005 Apr; 40(8):1181-7. PubMed ID: 15791520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
    Glesby MJ; Aberg JA; Kendall MA; Fichtenbaum CJ; Hafner R; Hall S; Grosskopf N; Zolopa AR; Gerber JG;
    Clin Pharmacol Ther; 2005 Aug; 78(2):143-53. PubMed ID: 16084849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.